Identification of a novel targeting peptide for cervical clear cell adenocarcinoma by in vivo phage display screening combined with immunofluorescent analysis

Background: Cervical clear cell adenocarcinoma (CCAC) is a subtype of cervical adenocarcinoma with distinct biological characteristics. Identification of a novel targeting peptide to advance the development of innovative diagnostic approaches and drug-targeted therapies for CCAC. Methods: In this study, we utilized in vivo phage display, a novel high-throughput screening technology, to identify tumor-targeting peptides for cervical carcinoma. The phage display peptide (Ph.D.-C7C™) library was screened three times, following which phage clones with a strong affinity for cervical cancer HeLa cells were identified. Subsequent phage detection and sequencing revealed the LLRSTGF peptide sequence, denoted as CCSP (cervical cancer specifically targeting peptide), responsible for binding to cervical cancer HeLa cells. CCSP was synthesized with 5-Carboxyfluorescein (5-FAM) fluorescent labeling, and its specificity and affinity were evaluated in both HeLa cells and clinical cervical tissues through immunofluorescent staining. Results: The results demonstrated that CCSP exhibited strong and specific binding to HeLa cells, particularly in the cell membrane and cytoplasm. Furthermore, CCSP displayed significant targeting capability towards CCAC tissues in human cervical cancer specimens, as indicated by intense fluorescent signals localized within the tumor cell membrane and cytoplasm. Conclusions: Our findings establish CCSP as a peptide that specifically interacts with CCAC, indicating that CCSP could hold potential as a targeting carrier for highly effective chemotherapy drugs, warranting further investigation.

Phage display; Cervical clear cell adenocarcinoma; Tumor-targeting peptides; Tumor targeting

[1] Kita M, Yasuhara Y, Sumi G, Yokoe T, Butsuhara Y, Hisamatsu Y, et al. Fertility-sparing radical resection of juvenile clear cell adenocarcinoma of the cervix by pneumovaginal endoscopic surgery. Gynecologic Oncology Reports. 2023; 45: 101135.

[2] Stolnicu S, Karpathiou G, Guerra E, Mateoiu C, Reques A, Garcia A, et al. Clear cell carcinoma (CCC) of the cervix is a human papillomavirus (HPV)-independent tumor associated with poor outcome: a comprehensive analysis of 58 cases. The American Journal of Surgical Pathology. 2022; 46: 765–773.

[3] Molijn A, Jenkins D, Chen W, Zhang X, Pirog E, Enqi W, et al. The complex relationship between human papillomavirus and cervical adenocarcinoma. International Journal of Cancer. 2016; 138: 409–416.

[4] Wang D, Zhao C, Fu L, Liu Y, Zhang W, Xu T. Primary clear cell adenocarcinoma of the cervix: a clinical analysis of 18 cases without exposure to diethylstilbestrol. Obstetrics and Gynecology International. 2019; 2019: 9465375.

[5] Wang T, Lu Z, Zhang X, Hua K. Factors associated with patient survival in clear cell adenocarcinoma of the cervix: a single-center experience in China. International Journal of General Medicine. 2022; 15: 4625–4634.

[6] André AS, Moutinho I, Dias JNR, Aires-da-Silva F. In vivo phage display: a promising selection strategy for the improvement of antibody targeting and drug delivery properties. Frontiers in Microbiology. 2022; 13: 962124.

[7] Zhang Y. Evolution of phage display libraries for therapeutic antibody discovery. mABs. 2023; 15: 2213793.

[8] Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996; 380: 364–366.

[9] Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998; 279: 377–380.

[10] Põšnograjeva K, Pleiko K, Haugas M, Teesalu T. New tools for streamlined in vivo homing peptide identification. Methods in Molecular Biology. 2022; 2383: 385–412.

[11] Newman MR, Benoit DSW. In vivo translation of peptide-targeted drug delivery systems discovered by phage display. Bioconjugate Chemistry. 2018; 29: 2161–2169.

[12] Dmitrieva MD, Voitova AA, Dymova MA, Richter VA, Kuligina EV. Tumor-targeting peptides search strategy for the delivery of therapeutic and diagnostic molecules to tumor cells. International Journal of Molecular Sciences. 2020; 22: 314.

[13] Soendergaard M, Newton-Northup JR, Deutscher SL. In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging. American Journal of Nuclear Medicine and Molecular Imaging. 2014; 4: 561–570.

[14] Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011; 32: 4943–4950.

[15] Lee KJ, Lee JH, Chung HK, Choi J, Park J, Park SS, et al. Novel peptides functionally targeting in vivo human lung cancer discovered by in vivo peptide displayed phage screening. Amino Acids. 2015; 47: 281–289.

[16] Lee KJ, Lee JH, Chung HK, Ju EJ, Song SY, Jeong S, et al. Application of peptide displaying phage as a novel diagnostic probe for human lung adenocarcinoma. Amino Acids. 2016; 48: 1079–1086.

[17] Li X, Pu X, Wang X, Wang J, Liao X, Huang Z, et al. A dual-targeting peptide for glioblastoma screened by phage display peptide library biopanning combined with affinity-adaptability analysis. International Journal of Pharmaceutics. 2023; 644: 123306.

[18] Bakhshinejad B, Sadeghizadeh M. Identification of a novel colon adenocarcinoma cell targeting peptide using phage display library biopanning. Biotechnology and Applied Biochemistry. 2022; 69: 2753–2765.

[19] Mandelin J, Cardó-Vila M, Driessen WHP, Mathew P, Navone NM, Lin S, et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proceedings of the National Academy of Sciences. 2015; 112: 3776–3781.

[20] Liu X, Peng J, He J, Li Q, Zhou J, Liang X, et al. Selection and identifcation of novel peptides specifcally targeting human cervical cancer. Amino Acids. 2018; 50:577–592.

[21] Kim J, She C, Potez M, Huang P, Wu Q, Prager BC, et al. Phage display targeting identifies eya1 as a regulator of glioblastoma stem cell maintenance and proliferation. Stem Cells. 2021; 39: 853–865.

[22] Wang K, Dai X, Yu A, Feng C, Liu K, Huang L. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression. Journal of Experimental and Clinical Cancer Research. 2022; 41: 289.